Ph II CABOGIST in GIST
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
A PHASE2 clinical study on Metastatic Gastrointestinal Stromal Tumor, this trial is completed. The trial is conducted by European Organisation for Research and Treatment of Cancer - EORTC and has accumulated 12 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Dec 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Dec 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
May 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bebington, United Kingdom , Bordeaux, France , Budapest, Hungary , Chelsea, United Kingdom , Leuven, Belgium , London, United Kingdom , Lyon, France , Manchester, United Kingdom , Mannheim, Germany , Prague, Czechia and 1 more location